Quantcast

Posts related to ‘Biotech’

Another Boost For Threshold (THLD)

Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) has been one of the top performing stocks of 2012.  Not just in emerging pharma and in biotech, but across the board.  Now we have ...
Read Full Story »

SciClone Raising Capital (SCLN)

SciClone Pharmaceuticals Inc. (NASDAQ: SCLN) has filed to raise capital, some for the company and some for its existing shareholders. The filing with the SEC includes the sale of any ...
Read Full Story »

VIVUS Scores FDA Backing For Qnexa Against Obesity (VVUS, OREX, ARNA)

VIVUS, Inc. (NASDAQ: VVUS) is going to likely have a huge day on Thursday.  The FDA panel reviewing its Qnexa drug to treat obesity has voted overwhelmingly to offer FDA panel backing ...
Read Full Story »

Crushing Blow for Gilead, Billions of Dollars (GILD)

Gilead Sciences Inc. (NASDAQ: GILD) is being crushed after a disappointing result in its Hepatitis C treatment after reporting that a majority of hepatitis C genotype-1 patients who had a ...
Read Full Story »

High-Premium Biotech M&A Continues (AMGN, CELG, MITI, IBB)

Thursday brought yet more merger and acquisition news in the ongoing buyout trends in the biotech sector.  Amgen Inc. (NASDAQ: AMGN) announced that it is going to acquire Micromet, Inc. (NASDAQ: ...
Read Full Story »

The $1,000 Genome Finally Arrives (LIFE)

Personalized medicine is coming... if you can afford it.  The quest for the $1,000 genomic map has been a race and it appears to be closer and closer.  News is out ...
Read Full Story »

Tracking Dividends in Biotech: Who Follows Amgen in Payouts? (AMGN, PFE, MRK, BIIB, CELG, ALXN, CBST, PDLI, REGN, VRTX)

For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at least some of the same problems of Big Pharma players like ...
Read Full Story »

Top Biotech Stock Picks For 2012 (ARIA, DNDN, GILD, HGSI, ILMN, INCY, JAZZ, LIFE, THRX, IBB, XBI)

The biotech sector has seen its share of ups and downs in 2011 and prior years.  It is almost always the case that some of the top performing stocks each ...
Read Full Story »

Small Caps With Over 50% Stock Upside in 2012 (PNK, CDXS, VVUS, SCMR)

Over the last week we have been reviewing some of the "Small Cap Stocking Stuffers" that features the top small cap ideas for 2012 from Credit Suisse.  After reviewing the ...
Read Full Story »

ARIAD Secures Much-Needed Capital for Trials, Commercialization, and Growth (ARIA)

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) is raising cash to help support the commercialization of ponatinib in patients with resistant or intolerant CML and additional clinical development of its investigational targeted ...
Read Full Story »

The ‘Double’ Call in Human Genome (HGSI)

Human Genome Sciences Inc. (NASDAQ: HGSI) is not getting much of a boost despite being called as stock which could manage to double in price over the next 18 months ...
Read Full Story »

Dendreon Raising $125 Million Via I.P. Sale (DNDN, MRK)

Dendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment.  Unfortunately, PROVENGE sales ran slower than expected after the FDA took forever to ...
Read Full Story »

Winners as Pfizer Loses Lipitor Patent (PFE, TEVA, MYL, WPI)

Pfizer Inc. (NYSE: PFE) has a big day ahead of it.  While it has been known for years, it is a massive date: Lipitor goes off-patent and will have generic ...
Read Full Story »

Sequenom Files To Raise Capital (SQNM)

Sequenom, Inc. (NASDAQ: SQNM) has just filed to raise up to $150 million in a mixed securities shelf offering.  The diagnostics company could sell any combination of Common Stock, Preferred ...
Read Full Story »

Another Bump Up for Dendreon and PROVENGE (DNDN)

Dendreon Corporation (NASDAQ: DNDN) is surging on news that the Centers for Medicare and Medicaid Services will now cover the infusion costs associated with the administration of PROVENGE.  Dendreon noted ...
Read Full Story »